Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
| ▸ | CETP | P11597 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492496 | 0.93 | CYP4F2 (0.49) | CYP4F2CYP4A11POLBPKMLMNA | |
| SCHEMBL11345271 | 0.93 | CYP4F2 (0.49) | CYP4F2CYP4A11CETPPOLBPKM | |
| SCHEMBL21399965 | 0.91 | CYP4F2 (0.47) | CYP4F2CYP4A11CETPPOLBPKM | |
| SCHEMBL6572234 | 0.91 | CYP4F2 (0.46) | CYP4F2CYP4A11POLBPKMLMNA | |
| SCHEMBL8071102 | 0.89 | CYP4F2 (0.45) | CYP4F2CYP4A11CETPPOLBPKM | |
| SCHEMBL27260326 | 0.88 | CYP4F2 (0.53) | CYP4F2CYP4A11CETP | |
| SCHEMBL798044 | 0.87 | CYP4F2 (0.53) | CYP4F2CYP4A11POLBPKMLMNA | |
| SCHEMBL14697097 | 0.87 | CYP4F2 (0.51) | CYP4F2CYP4A11CETP | |
| SCHEMBL8411261 | 0.87 | CYP4F2 (0.51) | CYP4F2CYP4A11CETP | |
| SCHEMBL14697386 | 0.87 | CYP4F2 (0.51) | CYP4F2CYP4A11CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022133215-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-06-23 | — | — | WO | disclosed |